What Could Stall AbbVie Stock's Run?

Nxera Pharma has signed a $1.47bn global licensing deal with AbbVie for NXE0033744, an IBD treatment. Nxera receives $100m upfront and potential milestone payments. The deal is subject to antitrust clearances. NXE0033744 targets unmet needs in IBD with a novel mechanism. AbbVie gains exclusive rights to develop and commercialize the drug.

J&J and Protagonist's Icotyde showed improvement in psoriatic arthritis in a Phase 3 trial, with 58% of patients achieving a 20% improvement in disease activity. However, analysts at BMO Capital Markets noted that the results fell short of AbbVie's Skyrizi, which has a 23% placebo-adjusted improvement. Skyrizi's stronger efficacy and dosing schedule may give it an edge, but Icotyde's oral administration could appeal to patients who prefer to avoid injections.

AbbVie ABBV reported that patients using GLP-1 weight-loss drugs showed improved facial satisfaction in two studies by its Allergan Aesthetics division. The studies, presented at a dermatology conference, involved 30 and 25 patients respectively, who received treatments like hyaluronic acid fillers and Botox. Participants reported significant improvements in facial appearance satisfaction and skin quality.

AbbVie (ABBV) reported that patients using GLP-1 weight-loss drugs showed improved facial satisfaction post-cosmetic treatments in two studies by its Allergan Aesthetics division, according to the company. The results were presented at a dermatologic surgery conference.

Nxera Pharma's subsidiary has signed a $1.47B global license deal with AbbVie for NXE0033744, a novel IBD drug. Nxera will receive $100M upfront and up to $1.37B in milestones. The deal is subject to antitrust clearances and the payment is expected to be recognized in Q4 2026.

Abbvie Inc. will pay Nxera Pharma Co. Ltd. $100 million upfront for global rights to NXE-0033744, an oral EP4 receptor agonist in phase II trials for inflammatory bowel disease, with potential additional payments.